

TYRATECHTM

PUTTING NATURE TO WORK






TyraTech is a natural life sciences company, a leader in safe and effective insect and parasite control

- ❖ Proprietary technology discovered at Vanderbilt-Ingram Cancer Center
- ❖ Founded in 2004, listed on London AIM market in 2007 (LON: TYR & TYRU)
- ❖ Headquartered in Research Triangle Park, North Carolina

TyraTech is at the commercialisation phase of developing its platforms




TyraTech's products can help control the devastating worldwide impact of insects and parasites



❖ Global impact on the health of adults and children


- Infections and allergies
- Transmission of diseases: Malaria, Lyme, West Nile disease ...
- Food contamination
- Impact on child development: 2bn people (mainly children) suffer parasitic infections from soil transmitted worms (WHO estimates)



Prevalence of Lyme disease
(in red)

❖ Global impact on animal health

- Transmission of diseases: Blue Tongue, Lyme, West Nile disease ...
- Productivity losses: ticks and tick-borne diseases in cattle cost each year globally up to \$19bn (FAO estimates*)
- Food contamination



West Nile virus prevalence in the
USA

*Source: FAO, State of Agriculture, 2009

TyraTech's novel insect control products answer a real market need



❖ Existing products (pesticides) suffer from performance and safety issues

- It is estimated that close to 1000 species of pests have evolved a resistance to a pesticide
- Most pesticides pose some risk of harm to humans, animals or the environment*
- These issues have led to drastic reductions in the use of synthetic products and more stringent regulatory requirements, including bans
- In addition, most benign alternatives and natural pesticides have not delivered an acceptable level of performance




TyraTech now offers an innovative solution to these issues, where customers do not have to compromise between safety and performance

- Patented technology delivers superior efficacy, comparable or superior to synthetics
- Nature-derived ingredients ensure highest level of safety for children, animals and the environment
- Unique formulations provide quality aesthetics, cosmetics and convenience

* U.S. Fish and Wildlife Service




TyraTech's highly potent solutions target G protein coupled receptors specific to invertebrates



- ❖ G protein-coupled receptors are the target of approximately 50% of all modern medicinal drugs*. R.Lefkowitz and B. Kobilka, received the Nobel prize in chemistry for 2012 for their work on understanding how GPCRs function
- ❖ TyraTech's unique screening platform focuses on the effects of oil blends on the tyramine receptor (one of these GPCRs) of insects and parasites
- ❖ This tyramine receptor is specific to invertebrates and is inactive in humans, providing a superior level of safety

* The Royal Swedish Academy of Sciences press release for the Nobel Prize in Chemistry (2012).


GPCR Mode of Action Screening




Extract
RNA/DNA
for GPCR
genes



Insert receptor gene
into animal cells



Verify receptor protein expression
by exposing cells to natural ligand
(i.e. tyramine)



Screen compounds
in fluorescence assays



TyraTech's unique product benefits



“A superior combination of performance, safety and convenience”

❖ Efficacy

- As efficacious as (or superior to) existing synthetic chemical pesticides
- Effective against resistant pests
- Scientifically proven

❖ Safety

- No synthetic chemical pesticides
- Superior level of safety for the environment, no residues
- No risk of food chain contamination
- Safely used in the presence of animals or children
- Safe for both topical and oral usage
- No restrictions on re-use

❖ Cosmetics & Convenience

- Highly convenient: no need for professional application
- Excellent cosmetics and aesthetics (natural fragrances, non-sticky)

TyraTech's products present a superior level of safety

- ❖ The oil blends consist of naturally occurring compounds found in a wide variety of fruits, vegetables and spices
- ❖ No adverse effects were observed in animal studies – even at 100 times the dose anticipated for humans*
- ❖ The compounds used in the Technology are widely considered safe:
 - FDA: Generally Recognized As Safe (GRAS)
 - EPA: FIFRA 25b Exempt - Minimum Risk Pesticide
 - FEMA GRAS ingredients
 - Joint FAO/WHO Expert Committee on Food Additives (JECFA) deemed safe for flavoring use
 - The Council of Europe deemed safe for flavoring use



World Health Organization



COUNCIL OF EUROPE
CONSEIL DE L'EUROPE



*TyraTech Functional Food Technology

Strong patent portfolio

❖ Approach:

- TyraTech employs a multi-layered patent approach
- Patents protect
 - Methods for screening compounds
 - Compositions effective against a wide range of target organisms
 - Combinations of active ingredients
- Ability to tailor portfolio to protect developing product lines and partnerships

❖ Status:

- Patents granted
 - 3 granted U.S. patents and 11 granted international patents
- Patent applications pending
 - 15 patent families, comprising 85 applications, being prosecuted in 19 countries

TyraTech will focus initially on three major segments for a total addressable market of \$9.5bn – \$12.5bn*

Personal Care

- ❖ Head Lice
- ❖ Repellent
- ❖ Functional Food



Market size
\$1bn – \$2bn*

Animal health

- ❖ Production animal facilities
- ❖ Repellent
- ❖ External parasites
- ❖ Internal parasites



Market size
\$5bn – \$6bn*

Pesticides

ENVANCE
TECHNOLOGIES

- ❖ Aerosols
- ❖ Tech Dust
- ❖ Drain Fly

TERMINIX
ULTIMATE PROTECTION



Market size
\$3.5bn – \$4.5bn*

POWERED BY TYRATECH

Note:1. Envance Technologies, LLC is a joint venture between TyraTech, Inc. and AMVAC; 2.* Management estimates

Summary and Outlook

❖ **TyraTech's products provide solutions to a global problem**

- Technology delivers products with efficacy proved to be as good or superior to the synthetic products currently in the market today without the safety issues
- Solutions are natural and non-toxic with resultant safety benefits acknowledged by global regulatory bodies
- Addressing market segments with a combined value of between \$9.5bn and \$12.5bn*

❖ **TyraTech has products in the market or ready to be commercialised**

- 6 pesticide products already in the market (retail and professional) at The Home Depot and other outlets through Envance Technologies
- 2 personal care products are registered and ready to be sold (Repellent, Head Lice)
- 6 animal health products ready to be sold for production animal premises

❖ **TyraTech has laid the foundation for fast-paced sustainable growth**

- Strategic objective to segment the market and expand in various distribution channels
- Significant product pipeline in place
- Geographical Expansion across fast-growing BRIC countries where insects and parasites are a major problem

*Management Estimates

Disclaimer

This presentation has been prepared by TyraTech, Inc. (the “Company”).

The information in this presentation is being given to you solely for your preliminary information on a confidential basis and neither it nor its contents may be reproduced, redistributed or passed on or disclosed, in whole or in part, to any other person. In particular, neither this presentation nor any copy thereof may be taken, transmitted, distributed or sent, directly or indirectly, in or into Australia, the Republic of South Africa, the Republic of Ireland, Japan or Canada or to any resident thereof or in or into the United States or to any US Person (as defined in Regulation S promulgated under the United States Securities Act of 1933 (as amended) (the “Securities Act”). The distribution of this presentation in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of any such other jurisdiction.

Within the United Kingdom this document is directed at and may only be communicated to persons who are both (a) “qualified investors” within the meaning of Article 2(1)(e) of the Prospectus Directive (“Qualified Investors”) or other persons to whom it may lawfully be distributed without giving rise to the requirement for a prospectus under the Prospectus Directive; and (b) either (i) persons who have professional experience in matters relating investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (“FSMA”) (Financial Promotion) Order 2005 (the “Order”); (ii) high net worth entities falling within Article 49 of the Order; or (iii) other persons to whom it may lawfully be communicated, (all such persons together known as “Relevant Persons”).

The content of this document has not been approved for distribution in the United Kingdom by an authorised person. Such approval is required by section 21 of FSMA unless an appropriate exemption applies. Reliance on this document for the purpose of engaging in any investment activity may expose a significant risk of losing all the property invested or of incurring additional liability. If you are in any doubt about the investment to which this document relates you should consult an independent financial adviser or other authorised person under the FSA who specialises in advising on the acquisition or disposal of shares and other securities.

Any investment or investment activity to which this document relates is available in the United Kingdom only to Relevant Persons. Any person who is not a Relevant Person should not act or rely on this presentation or any of its contents and any investment or investment activity to which it relates will only be available to Relevant Persons. Any person who is unsure of their position should seek independent advice.

This document does not constitute a prospectus, and does not constitute, or form part of, any offer to sell or issue, or any solicitation of subscriptions for the Company’s securities, nor should it be relied on in connection with any such sale, issue or subscription.

No Shares have been offered or sold, or will be offered or sold, to the public in any member state of the European Economic Area to anyone other than qualified investors as defined in the Prospectus Directive.

This document may be distributed in Switzerland to qualified Swiss investors only without the use of advertisements.

The information contained in this presentation is subject to updating, completion, verification and amendment and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. None of the Company, its shareholders or any of their respective affiliates, advisers (including Nplus1 Singer Capital Markets Limited) or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The forward-looking information contained herein has been prepared on the basis of a number of assumptions which may prove to be incorrect, and accordingly, actual results may vary. In any event, the value of investments can go up as well as down and past performance is not a guide to future returns.

The securities have not been and will not be registered under the Securities Act or under the securities laws of any state of the United States or under the applicable securities laws of Australia, the Republic of South Africa, the Republic of Ireland, Japan or Canada. Accordingly, subject to certain exceptions, such securities may not, directly or indirectly, be offered, sold, transferred, taken up or delivered in or into the United States of America, Australia, the Republic of South Africa, the Republic of Ireland, Japan or Canada or to or for the account or benefit of any national, resident or citizen of such countries or to any US Person as defined in Regulation S under the Securities Act. No action has been taken or will be taken by the Company or its shareholders or by Nplus1 Singer Capital Markets Limited that would permit a public offer of shares in the Company or possession or distribution of this presentation where action for that purpose is required.

The Shares have not been recommended by any United States federal or state securities commission or regulatory authority. The foregoing authorities have not confirmed the accuracy of or determined the adequacy of this document. Any representation to the contrary is a criminal offence in the United States. This document has been prepared pursuant to rules and requirements other than those promulgated under the United States federal securities laws and may not contain disclosures customary, expected or required in securities registration transactions prepared pursuant to the US rules and requirements.